Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis

Robert James Commons, R Grivas, Bart Currie

Research output: Contribution to journalArticlepeer-review


Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis. Predisposing risk factors are present in 80% of cases. Monoclonal antibodies are increasingly prescribed for varied medical conditions. This report describes the first known case of melioidosis in a patient whose only risk factor for disease is treatment with a monoclonal antibody. Prescribers of monoclonal antibodies and other immunosuppressants should ensure that their patients are aware of the potential risk of melioidosis prior to travel and the precautions that should be taken.
Original languageEnglish
Pages (from-to)1245-1246
Number of pages2
JournalInternal Medicine Journal
Issue number12a
Publication statusPublished - Dec 2014


Dive into the research topics of 'Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis'. Together they form a unique fingerprint.

Cite this